Early initiation of antiretroviral therapy and associated reduction in mortality, morbidity and defaulting in a nurse-managed, community cohort in Lesotho

AIDS

Volumn 24, Issue 17, 2010, Pages 2645-2650

  Ford, Nathan ^a,b   Kranzer, Katharina ^c   Hilderbrand, Katherine ^a   Jouquet, Guillaume ^a   Goemaere, Eric ^a   Vlahakis, Nathalie ^a   Triviño, Laura ^a   Makakole, Lipontso ^d   Bygrave, Helen ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d Scott Hospital   (Lesotho)

Author keywords

antiretroviral therapy; CD4 cell counts; early initiation; morbidity; mortality

Indexed keywords

STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; FOLLOW UP; HAZARD RATIO; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LESOTHO; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; NURSE MANAGER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SURVIVAL; WORLD HEALTH ORGANIZATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; LESOTHO; MALE; MIDDLE AGED; RESIDENCE CHARACTERISTICS; VIRAL LOAD;

EID: 78349243672     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833ec5b2     Document Type: Article

References (28)

1. WHO. Antiretroviral therapy for HIV infections in adults and adolescents: recommendations for a public health approach. Geneva: World Health Organization; 2006.
2. World Health Organisation. Rapidadvice: antiretroviraltherapy for HIV infection in adults and adolescents. World Health Organisation, Geneva, Switzerland; 2009.
3. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008; 9:65-71.
4. Department of Health and Human Services panel on antiretro-viral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 3 November, 2008; 1-139. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Accessed 15 January 2009].
5. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society\USA panel. JAMA 2008; 300:555-570.
6. Severe P, Jean Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363:257-265.
7. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baselineintheSMARTstudy. J Infect Dis 2008; 197:1133-1144.
8. Stockman F. US seeks to rein in AIDS program: overseas clinic costs have tripled to $7b in 6 years. Boston Globe; 2010.
9. Hirnshall G. The new WHO recommendations for HIV treat-ment. Geneva: World Health Organization; 2010.
10. MOHSW: Draft Lesotho National ART Guidelines. Maseru; 2007-2008.
11. Cohen R, Lynch S, Bygrave H, Eggers E, Vlahakis N, Hilderbrand K, et al. Antiretroviral treatmentoutcomes from a nurse-driven, community-supported HIV/AIDS treatment programme in rural Lesotho: observational cohort assessment at two years. J Int AIDS Soc 2009; 12:23.
12. Coviello V, Boggess M. Cumulative incidence estimation in the presence of competing risks. Stata J 2004; 4:103-112.
13. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Philips AN, Babiker A, Cohen CJ, et al. Major clinical outcomes in anti-retroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.J Infect Dis 2008;197: 1133-1144.
14. Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006; 42:464-469.
15. Harries AD, Zachariah R, Corbett EL, Lawn SD, Santos-Filho ET, Chimzizi R, et al. The HIV-associated tuberculosis epidemic: whenwillweact? Lancet2010; 375:1906-1919.
16. Fox M, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 2010; 15:1-15.
17. Charurat M, Oyegunle M, Benjamin R, Habib A, Eze E, Ele P, et al. Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS One 2010; 5:e10584.
18. Van Cutsem G, Hilderbrand K, Mathee S, Goemaere E, Coetzee D, Boulle A. Loss to follow-up and associated factors at different durations of antiretroviral therapy in Khayelitsha, South Africa. In: 5th IAS Conference on HIV Pathogenesis and Treatment. Abstract WEPEB284.
19. Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, et al., for the CEPAC-International Investigators. When to start antiretroviral therapy in resource-limited set-tings. Ann Intern Med 2009; 151:157-166.
20. Callaghan M, Ford N, Schneider H. Asystematic reviewof task shifting for HIV treatment and care in Africa. Hum Resour Health 2010; 8:8.
21. Cole SR, Li R, Anastos K, Detels R, Young M, Chmiel JS, Munoz A. Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies. Stat Med 2004; 23:3351-3363.
22. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, Kaharuza R, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364:1428-1434.
23. Badri M, Lawn SD, Wood R. Short-term riskofAIDSordeath in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet 2006; 368:1254-1259.
24. When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Philips AN, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363.
25. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al., NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826; Epub 2009 Apr 1.
26. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment pro-grammes in resource-limited settings: systematic review and metaanalysis. PLoS One 2009; 4:e5790.
27. Munderi P. When to start antiretroviral therapy in adults in low-income and middle-income countries: science and prac-tice. Curr Opin HIVAIDS 2010; 5:6-11.
28. Ford N, Calmy A, Hurst S. When to start antiretroviral therapy in resource-limited settings: a human rights analysis. BMC Int Health Hum Rights 2010; 10:6.